Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -596.89% | 4.14% | 20.57% | -38.26% | 117.26% |
| Total Depreciation and Amortization | -42.77% | -80.26% | -85.33% | -73.49% | -79.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.94% | 63.39% | -133.22% | 125.67% | -2,318.59% |
| Change in Net Operating Assets | -101.03% | -1,056.26% | -132.97% | 97.81% | -136.10% |
| Cash from Operations | -40.64% | -10.99% | -21.31% | -2.43% | 1.83% |
| Capital Expenditure | -55.77% | 82.88% | 80.11% | 98.73% | -93.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.21% | -302.55% | 189.21% | 125.04% | 244.34% |
| Cash from Investing | -99.38% | -305.73% | 192.16% | 126.86% | 246.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 393.98% | 1,730.77% | 1,010.53% | 133.33% | 591.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 46,491.57% | 1,089,723.08% | 1,010.53% | -99.98% | 591.67% |
| Foreign Exchange rate Adjustments | -100.00% | 103.57% | 700.00% | 87.50% | 312.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -283.24% | -190.18% | 119.78% | -140.09% | 147.71% |